INS and type 2 diabetes mellitus: In patients with type 2 diabetes, DPP-4 inhibition leads to higher levels of active incretins, both during fasting and post meal, which in turn lead to higher insulin release, lower glucagon levels, and improved fasting and post meal glucose concentrations.